Literature DB >> 34499866

Treatment of fibrotic interstitial lung disease: current approaches and future directions.

Kerri A Johannson1, Nazia Chaudhuri2, Ayodeji Adegunsoye3, Paul J Wolters4.   

Abstract

Fibrotic interstitial lung disease (ILD) represents a large group of pulmonary disorders that are often progressive and associated with high morbidity and early mortality. Important advancements in the past 10 years have enabled a better understanding, characterisation, and treatment of these diseases. This Series paper summarises the current approach to treatment of fibrotic ILDs, both pharmacological and non-pharmacological, including recent discoveries and practice-changing clinical trials. We further outline controversies and challenges, with discussion of evolving concepts and future research directions.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34499866     DOI: 10.1016/S0140-6736(21)01826-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  5 in total

Review 1.  Exploring the common pathophysiological links between IPF, SSc-ILD and post-COVID fibrosis.

Authors:  Rajesh Swarnakar; Yogesh Garje; Neeraj Markandeywar; Suyog Mehta
Journal:  Lung India       Date:  2022 May-Jun

2.  High intensity interval training versus moderate intensity continuous training for people with interstitial lung disease: protocol for a randomised controlled trial.

Authors:  Leona M Dowman; Anthony K May; Catherine J Hill; Janet Bondarenko; Lissa Spencer; Norman R Morris; Jennifer A Alison; James Walsh; Nicole S L Goh; Tamera Corte; Ian Glaspole; Daniel C Chambers; Christine F McDonald; Anne E Holland
Journal:  BMC Pulm Med       Date:  2021-11-10       Impact factor: 3.317

3.  Inequity and the Interstitium: Pushing Back on Disparities in Fibrosing Lung Disease in the United States and Canada.

Authors:  Adam W Gaffney; Anna J Podolanczuk
Journal:  Am J Respir Crit Care Med       Date:  2022-02-15       Impact factor: 30.528

Review 4.  Pharmacological treatment for connective tissue disease-associated interstitial lung involvement: Protocol for an overview of systematic reviews and meta-analyses.

Authors:  Fotini B Karassa; Konstantinos I Bougioukas; Eleftherios Pelechas; Anastasia Skalkou; Evangelia Argyriou; Anna-Bettina Haidich
Journal:  PLoS One       Date:  2022-08-03       Impact factor: 3.752

5.  Comparing outcomes of ILD patients managed in specialised versus non-specialised centres.

Authors:  Michael Kreuter; Lars Schwettmann; Pavo Marijic; Larissa Schwarzkopf; Werner Maier; Franziska Trudzinski
Journal:  Respir Res       Date:  2022-08-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.